ENZA-P in @TheLancetOncol
Lu-177 PSMA-617 + enzalutamide vs. enza alone:
● ↑PFS: 13.0 vs 7.8, hazard radio 0.43
● PSA90 response 78% vs 37%
● PSA50 response 93% vs. 68%
● no additional side effects
Incredible work from @drlouiseemmett @Prof_IanD & @ANZUPtrials team
Working together to improve patient outcomes with personalised medicine & precision oncology: theranostics. PET/CT, prostate cancer ☢️ Prof 🇦🇺


